Tag : TYPE 2 DIABETES MELLITUS

Continuous glucose monitoring has become an essential tool in modern diabetes management, providing insight into glucose patterns and variability not captured by  HbA1c alone. Current evidence indicates that glycemic assessment must extend beyond HbA1c, particularly for individuals with T2D who face an elevated risk of microvascular and cardiometabolic complications.1 Evolving clinical guidance supports a multidimensional approach to glycemia, positioning CGM as a critical instrument for therapy selection, titration, treatment intensification, and individualized lifestyle modification.1 At ATTD-ASIA 2025, Dr. Daphne Gardner from Singapore General Hospital highlighted the practical benefits of CGM in T2D management, emphasizing its role in detecting glycemic excursions, guiding therapy adjustments, and supporting patient-centered care.1

Psoriasis is a chronic inflammatory disorder characterized by systemic inflammation and elevated circulating levels of pro-inflammatory cytokines. This persistent inflammatory state has been implicated in immune-mediated injury across multiple organ systems, with particular involvement of renal tissues. However, few large-scale studies have evaluated whether psoriasis independently increases the risk of renal complications in type 2 diabetes mellitus (T2DM) patients receiving guideline-directed renoprotective therapies. A retrospective cohort study was performed by researchers in Texas to compare the risk of diabetic nephropathy, chronic kidney disease (CKD), end-stage renal disease (ESRD), and dialysis in T2DM patients with and without psoriasis who were receiving angiotensin-converting enzyme inhibitor (ACEI), angiotensin II receptor blocker (ARB) or sodium-glucose cotransporter-2 inhibitor (SGLT2i) therapies.